Zahedan Journal of Research in Medical Sciences

Published by: Kowsar

HLA DRB5*01 Association Survey with Multiple Sclerosis in Khuzestan Province of Iran

Tahereh Latifi Pakdehi 1 , Mohammad Shafiei 1 , * and Hamid Galehdari 1
Authors Information
1 Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz, Iran
Article information
  • Zahedan Journal of Research in Medical Sciences: August 2017, 19 (8); e9186
  • Published Online: August 31, 2017
  • Article Type: Research Article
  • Received: October 21, 2016
  • Revised: May 26, 2017
  • Accepted: June 27, 2017
  • DOI: 10.5812/zjrms.9186

To Cite: Latifi Pakdehi T, Shafiei M, Galehdari H. HLA DRB5*01 Association Survey with Multiple Sclerosis in Khuzestan Province of Iran, Zahedan J Res Med Sci. 2017 ; 19(8):e9186. doi: 10.5812/zjrms.9186.

Abstract
Copyright © 2017, Zahedan Journal of Research in Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Methods
3. Results
4. Discussion
Acknowledgements
Footnotes
References
  • 1. Korn T. Pathophysiology of multiple sclerosis. J Neurol. 2008; 255 Suppl 6: 2-6[DOI][PubMed]
  • 2. Pugliatti M, Harbo HF, Holmoy T, Kampman MT, Myhr KM, Riise T, et al. Environmental risk factors in multiple sclerosis. Acta Neurol Scand Suppl. 2008; 188: 34-40[DOI][PubMed]
  • 3. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev. 2010; 9(5)-94[DOI][PubMed]
  • 4. Daroff RB, Aminoff MJ. Encyclopedia of the neurological sciences. 2014;
  • 5. Browne P, Chandraratna D, Angood C, Tremlett H, Baker C, Taylor BV, et al. Atlas of Multiple Sclerosis 2013: A growing global problem with widespread inequity. Neurology. 2014; 83(11): 1022-4[DOI][PubMed]
  • 6. Etemadifar M, Abtahi SH. Multiple sclerosis in Isfahan, Iran: Past, Present and Future. Int J Prev Med. 2012; 3(5): 301-2[PubMed]
  • 7. Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler. 2011; 17(8): 1022-7[DOI][PubMed]
  • 8. Compston A, Coles A. Multiple sclerosis. Lancet. 2008; 372(9648): 1502-17[DOI][PubMed]
  • 9. O'Connor P, Canadian Multiple Sclerosis Working G. Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology. 2002; 59(6 Suppl 3)-33[PubMed]
  • 10. Shin RK. Multiple Sclerosis; Diagnosis. 2014; [DOI]
  • 11. Comabella M, Khoury SJ. Immunopathogenesis of multiple sclerosis. Clin Immunol. 2012; 142(1): 2-8[DOI][PubMed]
  • 12. Stadelmann C, Wegner C, Bruck W. Inflammation, demyelination, and degeneration - recent insights from MS pathology. Biochim Biophys Acta. 2011; 1812(2): 275-82[DOI][PubMed]
  • 13. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996; 46(4): 907-11[PubMed]
  • 14. Iuliano G, Napoletano R, Esposito A. Multiple sclerosis: relapses and timing of remissions. Eur Neurol. 2008; 59(1-2): 44-8[DOI][PubMed]
  • 15. Hoffjan S, Akkad DA. The genetics of multiple sclerosis: an update 2010. Mol Cell Probes. 2010; 24(5): 237-43[DOI][PubMed]
  • 16. Oksenberg JR, Barcellos LF. Multiple sclerosis genetics: leaving no stone unturned. Genes Immun. 2005; 6(5): 375-87[DOI][PubMed]
  • 17. Ramagopalan SV, Dobson R, Meier UC, Giovannoni G. Multiple sclerosis: risk factors, prodromes, and potential causal pathways. Lancet Neurol. 2010; 9(7): 727-39[DOI][PubMed]
  • 18. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol. 2007; 61(4): 288-99[DOI][PubMed]
  • 19. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol. 2007; 61(6): 504-13[DOI][PubMed]
  • 20. Willer CJ, Dyment DA, Sadovnick AD, Rothwell PM, Murray TJ, Ebers GC, et al. Timing of birth and risk of multiple sclerosis: population based study. BMJ. 2005; 330(7483): 120[DOI][PubMed]
  • 21. Marrie RA. Environmental risk factors in multiple sclerosis aetiology. Lancet Neurol. 2004; 3(12): 709-18[DOI][PubMed]
  • 22. Roudbari SA, Ansar MM, Yousefzad A. Smoking as a risk factor for development of Secondary Progressive Multiple Sclerosis: A study in IRAN, Guilan. J Neurol Sci. 2013; 330(1-2): 52-5[DOI][PubMed]
  • 23. Cree BA. Multiple sclerosis genetics. Handb Clin Neurol. 2014; 122: 193-209[DOI][PubMed]
  • 24. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 2004; 3(2): 104-10[PubMed]
  • 25. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012; 248(1): 87-103[DOI][PubMed]
  • 26. Bahreini SA, Jabalameli MR, Saadatnia M, Zahednasab H. The role of non-HLA single nucleotide polymorphisms in multiple sclerosis susceptibility. J Neuroimmunol. 2010; 229(1-2): 5-15[DOI][PubMed]
  • 27. Oksenberg JR, Baranzini SE, Sawcer S, Hauser SL. The genetics of multiple sclerosis: SNPs to pathways to pathogenesis. Nat Rev Genet. 2008; 9(7): 516-26[DOI][PubMed]
  • 28. Choo SY. The HLA system: genetics, immunology, clinical testing, and clinical implications. Yonsei Med J. 2007; 48(1): 11-23[DOI][PubMed]
  • 29. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 haplotype and multiple sclerosis: a HuGE review. Am J Epidemiol. 2007; 165(10): 1097-109[DOI][PubMed]
  • 30. Quandt JA, Huh J, Baig M, Yao K, Ito N, Bryant M, et al. Myelin basic protein-specific TCR/HLA-DRB5*01:01 transgenic mice support the etiologic role of DRB5*01:01 in multiple sclerosis. J Immunol. 2012; 189(6): 2897-908[DOI][PubMed]
  • 31. Fogdell A, Hillert J, Sachs C, Olerup O. The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. Tissue Antigens. 1995; 46(4): 333-6[PubMed]
  • 32. Caillier SJ, Briggs F, Cree BA, Baranzini SE, Fernandez-Vina M, Ramsay PP, et al. Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol. 2008; 181(8): 5473-80[PubMed]
  • 33. Brum DG, Barreira AA, dos Santos AC, Kaimen-Maciel DR, Matiello M, Costa RM, et al. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult Scler. 2010; 16(1): 21-9[DOI][PubMed]
  • 34. Fukazawa T, Kikuchi S, Sasaki H, Yabe I, Miyagishi R, Hamada T, et al. Genomic HLA profiles of MS in Hokkaido, Japan: important role of DPB1*0501 allele. J Neurol. 2000; 247(3): 175-8[PubMed]
  • 35. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50(1): 121-7[PubMed]
  • 36. Maloney S, Smith A, Furst DE, Myerson D, Rupert K, Evans PC, et al. Microchimerism of maternal origin persists into adult life. J Clin Invest. 1999; 104(1): 41-7[DOI][PubMed]
  • 37. Jersild C, Svejgaard A, Fog T. HL-A antigens and multiple sclerosis. Lancet. 1972; 1(7762): 1240-1[PubMed]
  • 38. Naito S, Namerow N, Mickey MR, Terasaki PI. Multiple sclerosis: association with HL-A3. Tissue Antigens. 1972; 2(1): 1-4[PubMed]
  • 39. Prat E, Tomaru U, Sabater L, Park DM, Granger R, Kruse N, et al. HLA-DRB5*0101 and -DRB1*1501 expression in the multiple sclerosis-associated HLA-DR15 haplotype. J Neuroimmunol. 2005; 167(1-2): 108-19[DOI][PubMed]
  • 40. Lang HL, Jacobsen H, Ikemizu S, Andersson C, Harlos K, Madsen L, et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol. 2002; 3(10): 940-3[DOI][PubMed]
  • 41. Gregersen JW, Kranc KR, Ke X, Svendsen P, Madsen LS, Thomsen AR, et al. Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature. 2006; 443(7111): 574-7[DOI][PubMed]
  • 42. Abedidni M, Habibi Saravi R, Zarvani A, Farahmand M. Epidemiologic study of multiple sclerosis in Mazandaran, Iran, 2007. J Mazandaran Univ Med Sci. 2008; 18(66): 82-6
  • 43. Alonso A, Cook SD, Maghzi AH, Divani AA. A case-control study of risk factors for multiple sclerosis in Iran. Mult Scler. 2011; 17(5): 550-5[DOI][PubMed]
  • 44. Etemadifar M, Sajjadi S, Nasr Z, Firoozeei TS, Abtahi SH, Akbari M, et al. Epidemiology of multiple sclerosis in Iran: a systematic review. Eur Neurol. 2013; 70(5-6): 356-63[DOI][PubMed]
  • 45. Kalanie H, Gharagozli K, Kalanie AR. Multiple sclerosis: report on 200 cases from Iran. Mult Scler. 2003; 9(1): 36-8[DOI][PubMed]
  • 46. Rezaali S, Khalilnezhad A, Naser Moghadasi A, Chaibakhsh S, Sahraian MA. Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. Iran J Neurol. 2013; 12(4): 136-43[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments